BeStock  
Stocks › Biotechnology › NVCT

Nuvectis Pharma NVCT

US equityMarket cap rank #3422Biotechnology
$19.39 −$0.45 (-2.27%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $19.39 0.00%
Open$19.60
Prev close$19.84
Day range$19.02 – $20.18
Volume301.6K
Market cap$666.80M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$31.05M-298.4% YoY
Net profit-$30.07M-303.0% YoY
Diluted EPS-$1.02-131.8% YoY
Free cash flow-$25.28M-462.5% YoY
Operating cash flow-$25.28M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-6.2MDec '24$-5.3MMar '25$-6.3MJun '25$-7.5MSep '25$-7.3MDec '25$-6.1MMar '26$-7.0MJun '26$-30.1MSep '26

Diluted EPS by quarter

-0.36Dec '24-0.27Mar '25-0.30Jun '25-0.44Sep '25-0.31Dec '25-0.26Mar '26-0.30Jun '26-1.02Sep '26

Free cash flow by quarter

$-2.5MDec '24$-4.2MMar '25$-3.4MJun '25$-4.5MSep '25$-4.0MDec '25$-6.5MMar '26$-4.5MJun '26$-25.3MSep '26

Annual revenue

$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-67.0%
Return on assets-57.2%
Return on invested capital-69.2%
Current ratio9.92
Liabilities / assets10.1%
Cash & investments$140.71M
Net cash (debt)$140.71M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $31.05M $7.20M $6.26M $27.57M $7.62M
Selling and Admin Expenses $3.68M $2.51M $2.15M $9.42M $2.53M
-General & Admin Expense $3.68M $2.51M $2.15M $9.42M $2.53M
Research & Development $27.37M $4.68M $4.11M $18.15M $5.09M
Operating Profit -$31.05M -$7.20M -$6.26M -$27.57M -$7.62M
Net Non-Operating Interest Income (Expense) $979,000.00 $177,000.00 $210,000.00 $1.13M $303,000.00
Non-Operating Interest Income $979,000.00 $177,000.00 $210,000.00 $1.13M $303,000.00
Pretax Profit -$30.07M -$7.02M -$6.05M -$26.44M -$7.31M
Net Profit -$30.07M -$7.02M -$6.05M -$26.44M -$7.31M
Profit from Continuing Operations -$30.07M -$7.02M -$6.05M -$26.44M -$7.31M
Net Income to Parent Company -$30.07M -$7.02M -$6.05M -$26.44M -$7.31M
Other Preferred Stock Dividends $0.00 – – $2.43M $0.00
Net Income to Common Stockholders -$30.07M -$7.02M -$6.05M -$28.87M -$7.31M
Basic EPS -$1.02 -$0.30 -$0.26 -$1.32 -$0.31
Diluted EPS -$1.02 -$0.30 -$0.26 -$1.32 -$0.31

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $140.84M $22.38M $25.40M $31.71M $31.71M
Total Current Assets $140.84M $22.38M $25.40M $31.71M $31.71M
Cash and Cash Equivalents & Short-Term Investments $140.71M $22.16M $25.13M $31.63M $31.63M
-Cash and Cash Equivalents $140.71M $22.16M $25.13M $31.63M $31.63M
Other Current Assets $132,000.00 $216,000.00 $268,000.00 $75,000.00 $75,000.00
Total Non-Current Assets $0.00 $0.00 $0.00 $0.00 $0.00
Total Liabilities $14.19M $13.29M $11.18M $13.30M $13.30M
Total Current Liabilities $14.19M $13.29M $11.18M $13.30M $13.30M
Payables $5.76M $5.18M $4.70M $6.27M $6.27M
-Accounts Payable $5.76M $5.18M $4.70M $6.27M $6.27M
Current Accrued Expenses $2.11M $92,000.00 $36,000.00 $115,000.00 $115,000.00
Total Non-Current Liabilities $0.00 $0.00 $0.00 $0.00 $0.00
Total Equity $126.65M $9.08M $14.22M $18.41M $18.41M
Stockholders' Equity $126.65M $9.08M $14.22M $18.41M $18.41M
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $269.47M $121.84M $119.96M $118.10M $118.10M
Retained Earnings -$142.83M -$112.76M -$105.74M -$99.69M -$99.69M
Current Deferred Liabilities – $1.39M – – –

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$25.28M -$4.53M -$6.51M -$16.01M -$3.97M
Net cash flow from continuing operations -$25.28M -$4.53M -$6.51M -$16.01M -$3.97M
Net Income from Continuing Operations -$30.07M -$7.02M -$6.05M -$26.44M -$7.31M
Change in Working Capital $2.37M $780,000.00 -$2.31M $4.40M $1.86M
-Change in Payables and Accrued Expense $2.59M $1.01M -$2.12M $3.05M -$115,000.00
-Change in Other Current Assets $84,000.00 $52,000.00 -$193,000.00 -$1,000.00 $70,000.00
-Change In Other Working Capital -$307,000.00 – – $1.35M $1.91M
Net cash flow from investing $0.00 $0.00 $0.00 $0.00 $0.00
Financing Cash Flow $143.83M $1.56M $7,000.00 $29.11M $166,000.00
Net Cash Flow from Continuing Financing Activities $143.83M $1.56M $7,000.00 $29.11M $166,000.00
Net Common Stock Issuance $153.10M $1.57M $7,000.00 $31.21M $248,000.00
Net Other Financing Charges -$9.41M – – -$2.10M -$82,000.00
Ending Cash Balance $140.71M $22.16M $25.13M $31.63M $31.63M
Net Change in Cash $118.55M -$2.97M -$6.50M $13.10M -$3.81M
Beginning Cash Balance $22.16M $25.13M $31.63M $18.53M $35.44M
Free Cash Flow -$25.28M -$4.53M -$6.51M -$16.01M -$3.97M

Discussion

No comments yet — be the first to weigh in on NVCT.

Sign in to join the discussion.

Scroll to Top